A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group

Trial Profile

A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction for the CTEP-Sponsored Organ Dysfunction Working Group

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2013

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Myeloproliferative disorders; Solid tumours
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 04 Mar 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top